ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Eisai Co., Ltd.

  • 5,874.00 JPY
  • -96.00
  • -1.61%
  • Japan
    Jul 19, 2019
  • Ticker
    TKS(4523)
  • Prev. close
    5,970
  • Market cap (JPY)
    1,770.50B
  • Market cap (USD)
    16,445.33M
  • Shares
    296.56M

Business Summary

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2019 JPYUSD
Revenue642,834M5,796.79M
Gross Profit446,436M4,025.76M
Operating income99,921M901.04M
Income before tax89,454M806.65M
Net income63,386M571.58M
EBITDA126,762M1,143.08M
Diluted EPS221.111.99
Dividends Per Share1501.35
Total Assets1,071.52B9,680.80M
Total liabilities419,539M3,790.38M
Total equity628,120M5,674.84M
Operating cash flow103,714M935.24M
Currency in JPYCurrency in USD

Historical Data

 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 548,465M 547,922M 539,097M 600,054M 642,834M
Gross Profit 340,580M 339,839M 331,091M 386,599M 446,436M
Operating income 27,778M 42,779M 51,205M 75,595M 99,921M
Income before tax 25,875M 50,473M 57,668M 76,803M 89,454M
Net income 43,254M 54,933M 39,359M 51,845M 63,386M
EBITDA 66,718M 76,843M 77,689M 101,778M 126,762M
Diluted EPS 151.37 191.76 137.41 180.97 221.11
Dividends Per Share 150 150 150 150 150
Total Assets 1,053.81B 973,987M 1,030.76B 1,049.03B 1,071.52B
Total liabilities 451,757M 397,159M 428,172M 434,934M 419,539M
Total equity 598,748M 573,660M 584,630M 593,582M 628,120M
Operating cash flow 76,022M 95,617M 75,851M 149,649M 103,714M
 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 4,992.55M 4,562.81M 4,978.38M 5,414.06M 5,796.79M
Gross Profit 3,100.22M 2,830.00M 3,057.51M 3,488.14M 4,025.76M
Operating income 252.85M 356.24M 472.86M 682.06M 901.04M
Income before tax 235.53M 420.31M 532.54M 692.96M 806.65M
Net income 393.73M 457.45M 363.46M 467.77M 571.58M
EBITDA 607.31M 639.90M 717.43M 918.30M 1,143.08M
Diluted EPS 1.37 1.59 1.26 1.63 1.99
Dividends Per Share 1.36 1.24 1.38 1.35 1.35
Total Assets 8,787.30M 8,665.75M 9,250.32M 9,863.94M 9,680.80M
Total liabilities 3,766.99M 3,533.60M 3,842.51M 4,089.64M 3,790.38M
Total equity 4,992.68M 5,103.96M 5,246.61M 5,581.39M 5,674.84M
Operating cash flow 692.01M 796.24M 700.45M 1,350.22M 935.24M

Valuation Measures

Mar 2019
PER28.06
ROA5.97%
ROE10.37%
Operating margin15.54%
Profit margin9.86%

Key executives

  • Chief Executive Officer & Representative Director: Haruo Naito
  • Chief Financial Officer & Chief IR Officer: Ryohei Yanagi
  • Chief Compliance Officer & Executive Officer: Junichi Asatani
  • Vice President: Yasunobu Kai
  • Vice President, Chief Planning Officer: Mitsuaki Tanaka

Shareholders

  • Wellington Management Co. LLP (8.6%)
  • Nomura Asset Management Co., Ltd. (5.0%)
  • Nippon Life Insurance Co. (4.1%)
  • Eisai Co., Ltd. (3.3%)
  • Nikko Asset Management Co., Ltd. (2.7%)
  • Daiwa Asset Management Co. Ltd. (2.5%)
  • Resona Holdings, Inc. (2.4%)
  • Sumitomo Mitsui Trust Asset Management Co., Ltd. (2.4%)
  • The Vanguard Group, Inc. (2.3%)
  • Mizuho Bank Pension Fund (1.8%)

Contact Details

  • Website:http://www.eisai.co.jp
  • Address: 4-6-10 Koishikawa, Bunkyo-Ku, Tokyo, 112-8088, Japan
  • Phone: +81.3.3817.3700

Related Companies

  • Eisai LLC
  • Eisai Machinery China Co. Ltd.
  • Eisai Laboratorios S de RL de CV
  • Eisai GesmbH
  • Eisai Farmaceutica, Unipessoal Lda.
  • Eisai Clinical Research Singapore Pte Ltd.
  • Eisai Ltd. (Canada)
  • Eisai SA/NV
  • Eisai (Malaysia) Sdn. Bhd.
  • Eisai (Thailand) Marketing Co. Ltd.
  • Eisai AB
  • Eisai Pharma AG
  • Eisai (Singapore) Pte Ltd.
  • Eisai Co. Ltd. /Misato Factory/
  • Eisai Board Incentive Plan
  • Eisai Corporate Pension Fund
  • Eisai Pension Fund
  • Eisai China, Inc.
  • H3 Biomedicine, Inc.
  • Herusu Co., Ltd.
  • Gakuen Shoji Co., Ltd.
  • PT Eisai Indonesia
  • Eisai Taiwan, Inc.
  • Eisai (Hong Kong) Co. Ltd.
  • Eisai Australia Pty Ltd.
  • Eisai Pharmaceuticals India Pvt Ltd.
  • Eisai GmbH
  • Eisai SRL
  • Eisai London Research Laboratories Ltd.
  • Ea Pharma Co., Ltd.

Competitors

  • Celltrion Pharm Inc.
  • MorphoSys AG
  • Nektar Therapeutics
  • Ipsen SA
  • Celgene Corporation
  • Denali Therapeutics Inc.
  • ArQule, Inc.
  • Exelixis, Inc.
  • Blueprint Medicines Corp.
  • Xenon Pharmaceuticals Inc.
  • Genfit SA
  • SillaJen, Inc.
  • Aslan Pharmaceuticals Ltd.
  • Mirati Therapeutics Inc.
  • Seattle Genetics, Inc.
  • Aquestive Therapeutics, Inc.
  • arGEN-X SE
  • AC Immune SA
  • Cortexyme, Inc.
  • Vivoryon Therapeutics AG
  • Heron Therapeutics Inc
  • Onxeo SA
  • ProMIS Neurosciences Inc.
  • Aileron Therapeutics, Inc.
  • Cytokinetics, Incorporated
  • Onconova Therapeutics Inc.
  • Radius Health Inc
  • VIVUS, Inc.
  • ACADIA Pharmaceuticals Inc.
  • AVEO Pharmaceuticals, Inc.
Last Updated on 19 Jul, 2019

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends June 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media